#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Subdural haematoma Hypereosinophilic syndrome Anti-neutrophil cytoplasmic antibody positive vasculitis Chronic lymphocytic leukaemia refractory Squamous cell carcinoma of head and neck Hodgkin's disease recurrent Marginal zone lymphoma Pleomorphic leiomyosarcoma Adenomatous polyposis coli Nephropathy Fungal infection Retinal artery occlusion Arrhythmogenic right ventricular dysplasia Anal cancer recurrent Bone marrow disorder More trials…

    Learn about Rare Diseases

    Myxofibrosarcoma – Life with Disease Hypereosinophilic syndrome – Treatment Loeys-Dietz syndrome Marginal zone lymphoma refractory – Treatment Atypical teratoid/rhabdoid tumour of CNS – Treatment Crigler-Najjar syndrome – Diagnostics Familial haemophagocytic lymphohistiocytosis – Basic Information Turner’s syndrome – Treatment Anaplastic thyroid cancer – Basic Information Optic glioma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Hdp-101 Canis Familiaris (553) Mitazalimab Bi 1015550 Timolol Maleate SULBACTAM SODIUM TRIACYLGLYCEROL LIPASE Clonazepam Zagociguat AGA2118 Povorcitinib Psilocybine VANADIUM OXIDE SULFATE Paclitaxel Obaluronate Metolazone Cangrelor Tetrasodium HYDROGEN Tasimelteon Antithrombin Iii Human Heparin Calcium More therapies…

    Learn about Your Condition

    Peripheral ischaemia Ehlers-Danlos syndrome Coronary artery dissection Vulvovaginal dryness Scoliosis Peripheral artery stenosis BRAF gene mutation Pyelonephritis acute Osteonecrosis of jaw Haemorrhage intracranial Metabolic disorder Breast cancer stage I Sleep disorder Breast conserving surgery Psoriasis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hypereosinophilic syndrome

  • Study of Benralizumab Safety, Pharmacokinetics, and Efficacy in Children with Eosinophilic Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Eosinophilic granulomatosis with polyangiitis
    • Hypereosinophilic syndrome
    Investigated Drugs:
    • Benralizumab
    France The Netherlands Poland

  • A Study of Depemokimab and Prednisolone in Adults with Hypereosinophilic Syndrome (HES)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypereosinophilic syndrome
    Investigated Drugs:
    • Depemokimab
    • Prednisolone
    Belgium Czechia Denmark Germany Greece Italy +3

  • Access to Mepolizumab for Patients with Hypereosinophilic Syndrome

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hypereosinophilic syndrome
    Investigated Drugs:
    • Mepolizumab
    Poland

  • Study on Mepolizumab for Children and Teens with Hypereosinophilic Syndrome

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hypereosinophilic syndrome
    Investigated Drugs:
    • Mepolizumab
    The Netherlands Spain

  • Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hypereosinophilic syndrome
    Investigated Drugs:
    • Benralizumab
    Austria Belgium Denmark France Germany Italy +3

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!